AOD-9604 cost and pricing: what you actually get for the money

Last updated 2026-07-24

How much does AOD-9604 actually cost per vial or dose?

Prices for AOD-9604 sold through research chemical suppliers and compounding-adjacent channels generally run from about $60 to $200 or more per vial, with vial sizes commonly labeled anywhere from 2mg to 10mg. That's a wide range, and it's wide for a reason: there's no FDA-approved dosage form to anchor pricing against, so every seller sets its own price based on purity claims, batch testing, and brand markup rather than a standardized cost basis. AOD-9604 has never appeared in the FDA's Drugs@FDA database of approved products ^[1], which means there's no NDC-listed, insurance-billable version to compare street prices against. Anything you buy is either a research-use product or a compounded preparation, and neither has a regulated price ceiling or floor. A rough monthly cost, assuming daily or near-daily dosing at typical protocol levels discussed in aod 9604 dosage guides, lands somewhere between $150 and $400 depending on vial size, dosing frequency, and whether you're buying single vials or multi-vial bundles. That's a real range people quote, not a guarantee of what any specific seller charges. The honest framing: you're not pricing a drug with known manufacturing costs and a competitive generic market. You're pricing a peptide sold in a gray zone, where the spread between cheapest and most expensive sellers can be three or four times over for what's marketed as the same product.

Why is there no standard, regulated price for AOD-9604?

There's no standard price because AOD-9604 sits outside the FDA approval system entirely. It has not gone through the New Drug Application process, and it does not appear on either FDA bulk drug substance list that governs what compounding pharmacies can legally use. Under 21 CFR 216.23, the 503A bulks list names specific substances pharmacies may compound with for individual patients, and under 21 CFR 216.24, the 503B list covers substances outsourcing facilities may use ^[2][3]. AOD-9604 is not on either list. The FDA's own bulk drug substances page for 503A compounding lays out the nomination and review process substances go through before they're added ^[4], and the current nominated-substances list ^[5] is where a compound would appear while under review, not after approval. Separately, 21 U.S.C. 353a governs the conditions under which pharmacy compounding is exempt from full new-drug requirements, generally tied to a valid prescription and non-commercial-scale preparation ^[6]. Because AOD-9604 falls outside the approved and bulks-list framework, pricing isn't shaped by insurance formularies, pharmacy benefit negotiations, or generic competition. It's shaped by whatever a given seller thinks the market will bear, and that's why you'll see the same nominal product priced at wildly different points.

Does the price reflect how well AOD-9604 actually works for fat loss?

No, and this is the part that matters most before you look at any invoice. AOD-9604 is a 15,000 dalton fragment of human growth hormone (hGH), specifically the C-terminal region researchers hoped would retain hGH's fat-metabolizing activity without its growth-promoting and blood-sugar effects. The idea had a real scientific rationale, and a 2004 review in Current Opinion in Investigational Drugs summarized fragment-based hGH research including AOD-9604 as a candidate specifically engineered around that lipolytic fragment concept ^[7]. But rationale isn't outcome. A 2006 review of obesity drugs in clinical development covered AOD-9604 among a field of candidate obesity therapies, most of which never made it to market or failed to separate from placebo in later trials ^[8]. The peptide went through human obesity trials, and the weight-loss results did not convincingly beat placebo. That's the central fact anyone spending money on this compound needs to sit with before anything else. So when a seller prices a vial at $150 versus $80, that price difference tells you nothing about efficacy. Neither number is anchored to a trial result showing meaningful fat loss over placebo. You're paying for purity testing, packaging, and seller reputation, not for a proven outcome. Compare that to approved obesity pharmacotherapies, which went through Phase 3 trials with placebo-controlled weight loss endpoints before earning FDA approval and a listing in Drugs@FDA ^[1]. That's a fundamentally different evidence bar than anything AOD-9604 has cleared.

What's actually in the price: purity testing, sourcing, and vial size?

Three things drive most of the price variation you'll see: claimed purity/testing documentation, vial mass (how many mg per vial), and where the seller sits in the supply chain. Certificates of analysis, when sellers provide them, add cost because third-party mass spectrometry or HPLC testing isn't free. A vial with a real, verifiable certificate from an independent lab should cost more than one with no documentation at all, and that premium is arguably worth paying if you're going to use the product anyway, because at least you know what's in the vial matches the label. Vial size matters more than most buyers realize when comparing prices. A $90 2mg vial and a $160 5mg vial aren't comparable on price alone; work out cost per mg before deciding which is the better deal. Sellers sometimes advertise the lower vial price to look cheaper while charging more per mg overall. Supply chain position (direct-from-source versus reseller versus repackaged) also shifts price, though it's the hardest factor for a buyer to verify from outside. This is also where reconstitution technique matters for getting real value out of what you bought; see aod 9604 how to reconstitute for the practical steps, since a botched reconstitution wastes product regardless of what you paid for it.

Is AOD-9604 cheaper or more expensive than other fat-loss peptides or drugs?

AOD-9604 sits in the middle of the peptide research-chemical price range, not at the top or bottom, but the comparison that matters isn't peptide-to-peptide. It's AOD-9604 versus approved obesity treatments with actual trial-proven weight loss. GLP-1 receptor agonists approved for chronic weight management went through large placebo-controlled Phase 3 programs before FDA approval, and those trials are listed with their approval data in Drugs@FDA ^[1]. Monthly costs for those approved drugs, before insurance, commonly run several hundred to over a thousand dollars depending on the specific product and dose, and that expense at least buys you a treatment with a demonstrated, statistically significant weight loss advantage over placebo in the trials that earned approval. AOD-9604, by contrast, is priced lower per month in most research-chemical marketplaces, often in that $150-$400 range discussed above, but it's priced lower for a compound whose own obesity trials didn't clear the placebo bar convincingly ^[7][8]. Cheaper isn't a bargain if the thing you're buying doesn't do the job. If you're deciding between spending on AOD-9604 versus an approved option, the honest math has to include the probability the compound works at all, more than the sticker price. For a fuller breakdown of what the peptide is and where the trial evidence actually stands, see aod 9604 peptide.

Are cheaper AOD-9604 sources riskier, or is price just marketing?

Price alone isn't a reliable signal of risk, but very cheap, undocumented vials are a real red flag worth taking seriously. A seller offering AOD-9604 far below the typical $60-$200 vial range, with no certificate of analysis and no clear sourcing information, is more likely cutting corners on purity, storage, or actual peptide content than passing along a genuine discount. That said, expensive doesn't automatically mean safe or effective either. There's no regulatory body verifying that a $200 vial contains more real peptide or less contamination than a $90 vial; both exist outside FDA oversight. The only real signal is documentation: does the seller provide a batch-specific certificate of analysis from an independent lab, and can you verify that lab actually exists and tested that batch. If you want a provider-reviewed path rather than an anonymous marketplace listing, AOD-9604 Co reviews providers and points to a fulfilling pharmacy partner rather than compounding or manufacturing anything itself. That's a meaningfully different risk profile than an unverified online listing with no traceable sourcing, and it's worth the modest price difference if it exists between the two. For what the side effect profile looks like regardless of source quality, see aod 9604 peptide side effects.

Does AOD-9604 show up on a drug test, and does that affect cost calculations?

AOD-9604 does not trigger a positive result on the World Anti-Doping Agency's standard hGH isoform immunoassay, according to a 2013 study in Drug Testing and Analysis that specifically tested whether the fragment cross-reacts with that screening method ^[9]. That study concluded AOD-9604 doesn't interfere with the isoform test WADA uses to detect exogenous hGH. That doesn't mean AOD-9604 is undetectable by all methods, though. Separate analytical work has focused specifically on detecting AOD-9604 and similar small peptides in doping controls using more targeted methods. A 2014 paper in the Journal of Pharmaceutical and Biomedical Analysis covered analytical approaches for detecting emerging therapeutics and non-approved drugs including peptides like AOD-9604 in human doping controls ^[10], and a companion 2014 review in Expert Review of Proteomics covered detection strategies for peptidic drugs, candidates, and analogs in sports doping specifically ^[11]. A 2016 method in the Journal of Separation Science described a direct urine injection, liquid chromatography, and ion mobility mass spectrometry approach built to screen for peptides under 2 kDa, which is smaller than AOD-9604's roughly 15,000 dalton fragment size but reflects the direction anti-doping labs are moving toward broader small-peptide detection ^[12]. For anyone weighing cost against risk in a tested athletic context, that's a separate calculation from the fat-loss efficacy question, and it's worth treating them as two distinct problems rather than assuming one signal (won't show on the standard immunoassay) settles the other (will a targeted method catch it).

What does a realistic monthly AOD-9604 budget look like?

A realistic monthly budget for someone following a typical daily or near-daily protocol runs roughly $150 to $400, driven mostly by vial size, dosing frequency, and seller pricing tier. Below is a rough breakdown based on the vial pricing range discussed above; treat these as illustrative math, not quoted prices from any specific seller.

Larger vials generally lower your cost per mg, which is the standard economics of buying more volume at once, but it also means committing more money upfront to a compound whose own trial record didn't show clear separation from placebo for fat loss ^[7][8]. That's the tradeoff: bulk buying saves money per dose but increases total dollars at risk if the product doesn't deliver the outcome you're hoping for. Before setting a budget, work out your actual dosing plan using something like the aod 9604 dosage calculator so you're pricing against a real protocol rather than a guess.

Is AOD-9604 worth the money given the trial results?

Based on the human trial record, AOD-9604 is a hard sell purely on fat-loss grounds. The fragment rationale was genuinely reasonable at the time researchers designed it: take the piece of hGH thought to drive lipolysis (fat breakdown) and strip out the growth-hormone-receptor-binding region responsible for the side effects that make full hGH risky for chronic obesity treatment. That's sound peptide engineering logic, and it's exactly the kind of hypothesis worth testing in trials ^[7]. But testing it is what happened, and the results didn't hold up. AOD-9604 went through human obesity trials, and weight-loss outcomes did not separate convincingly from placebo. A 2006 review of obesity drugs in clinical development placed AOD-9604 among the broader field of candidates that entered development without emerging as approved therapies ^[8]. That's not a smear, it's just where the compound's own evidence landed. More recent literature has focused on AOD-9604 in different contexts entirely. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews covered therapeutic peptides in orthopaedics broadly, including applications, challenges, and future directions for peptides used in musculoskeletal contexts ^[13]. A related 2026 paper in Sports Medicine covered safety and efficacy of approved and unapproved peptide therapies specifically for musculoskeletal injuries and athletic performance ^[14]. Neither of those papers is a fat-loss efficacy trial, and citing them to support a weight-loss claim would misrepresent what they actually studied. If you're spending money on AOD-9604 hoping for orthopaedic or recovery benefits, that's a different, more current research thread than the original 2004-era obesity trial data, and it deserves its own honest look rather than being folded into a fat-loss pitch. The money-honest answer: if fat loss is your primary goal, AOD-9604's own trial data doesn't support spending real money on it over approved options with placebo-beating Phase 3 results. If you're going in anyway for other reasons, buy from a provider-reviewed source rather than the cheapest anonymous listing, verify vial size before comparing prices, and go in knowing exactly what the evidence does and doesn't show.

How do the 2003-2005 'Gateways to clinical trials' entries factor into pricing or evidence?

They don't add pricing information, but they're worth knowing about because they show AOD-9604 was tracked as an active clinical development candidate across multiple entries. Three separate 'Gateways to clinical trials' roundups in Methods and Findings in Experimental and Clinical Pharmacology, published in 2003 and 2005, listed AOD-9604 among compounds moving through development pipelines during that period ^[15][16][17]. Those entries function as development-tracking snapshots rather than efficacy studies; they tell you the compound was in active trials during that window, not what the trials found. Combined with the 2004 and 2006 reviews covering the actual fragment rationale and obesity drug pipeline outcomes ^[7][8], the picture is consistent: AOD-9604 had real momentum as a candidate in the mid-2000s, went through the trial process, and the obesity efficacy signal didn't hold up strongly enough to result in approval. That matters for a cost-and-pricing article specifically because it explains why AOD-9604 never got the price stabilization that comes with FDA approval. Approved drugs get NDC codes, insurance negotiation, and generic competition once patents expire, all of which push prices toward a predictable range. A compound that entered trials, didn't clear the bar, and never got approved just stays in the unregulated research-chemical price zone indefinitely, which is exactly where AOD-9604 sits today.

Where can I find AOD-9604 and how do prices compare across sources?

If you've weighed the evidence and still want to move forward, the two practical paths are an anonymous research-chemical marketplace or a provider-reviewed route with documented sourcing. See aod 9604 peptide for sale for a fuller breakdown of what to look for in a listing, including certificate of analysis practices and vial labeling standards. Across marketplaces, expect the $60-$200+ per vial range discussed throughout this article, with the widest spread coming from purity documentation and vial size rather than any meaningful product difference. Sellers offering steep discounts with no testing documentation are the ones to be most skeptical of, not necessarily because they're scams, but because you have no way to verify what's actually in the vial. AOD-9604 Co reviews providers rather than compounding or selling product directly, and points toward a fulfilling pharmacy partner for readers who want a documented sourcing chain instead of an anonymous listing. That's a sourcing-quality decision, though, not an efficacy one. No amount of good sourcing changes what the human obesity trials showed about weight loss versus placebo ^[7][8].

Frequently asked questions

How much does AOD-9604 cost per vial?

Typical pricing runs $60 to $200 or more per vial, depending on vial size (commonly 2mg to 10mg) and whether the seller provides third-party purity testing. There's no regulated price because AOD-9604 isn't FDA-approved and doesn't appear on the FDA's compounding bulks lists ^[1][2][3], so prices vary widely by seller.

Why is AOD-9604 not covered by insurance?

Insurance only covers FDA-approved drugs listed in the Drugs@FDA database with an NDC code, and AOD-9604 has never gone through that approval process ^[1]. It's also absent from both FDA compounding bulks lists ^[2][3], so it can't be billed as a standard compounded prescription either.

Is AOD-9604 cheaper than prescription weight-loss drugs?

Per month, AOD-9604 often costs less than approved GLP-1 weight-loss drugs, which can run several hundred to over a thousand dollars monthly before insurance. But the approved drugs have placebo-controlled Phase 3 trial data behind their FDA listing ^[1], while AOD-9604's own obesity trials didn't show a clear weight-loss advantage over placebo ^[7][8].

Does a higher price mean better quality or purity?

Not reliably. Price differences mostly reflect vial size, whether a certificate of analysis is provided, and seller markup, not verified purity differences. A well-documented $90 vial can be more trustworthy than an undocumented $180 vial. Always check for an independent lab's certificate of analysis rather than relying on price as a quality signal.

What's a realistic monthly budget for an AOD-9604 protocol?

Most daily or near-daily protocols run roughly $150 to $400 a month, depending on vial size and dosing frequency. Larger vials (10mg) usually lower your cost per mg compared to smaller 2mg vials, but require more upfront spending. Work out your actual planned dose before budgeting, since price-per-vial alone is misleading.

Did AOD-9604 actually work in human fat-loss trials?

AOD-9604 went through human obesity trials, and the weight-loss results did not separate convincingly from placebo. A 2006 review of obesity drugs in development covered AOD-9604 among candidates that didn't progress to approval ^[8]. The fragment rationale, targeting hGH's lipolytic region while avoiding growth effects, was sound science ^[7], but the trial outcomes didn't confirm the hypothesis strongly enough for approval.

Will AOD-9604 show up on a drug test?

A 2013 study in Drug Testing and Analysis found AOD-9604 does not influence the WADA hGH isoform immunoassay, the standard screening test for exogenous growth hormone ^[9]. However, separate targeted detection methods for small peptides in doping controls have been developed ^[10][11][12], so 'doesn't trigger the standard test' isn't the same as 'undetectable by all methods.'

Is cheap AOD-9604 a red flag?

Very cheap vials with no certificate of analysis and no clear sourcing information are a real concern, more likely to involve underdosed or contaminated product than a genuine bargain. Price alone isn't proof of risk, but the combination of unusually low price plus zero documentation is the pattern worth avoiding.

What determines AOD-9604 vial pricing besides the peptide itself?

Three main factors: claimed purity and independent lab testing documentation, vial mass in mg, and the seller's position in the supply chain (direct source versus reseller). None of these factors relate to proven fat-loss efficacy, since the underlying trial data didn't show AOD-9604 beating placebo for weight loss ^[7][8].

Is AOD-9604 legal to buy in the United States?

AOD-9604 is not FDA-approved and doesn't appear on either FDA compounding bulks list under 21 CFR 216.23 or 216.24 ^[2][3]. It's typically sold as a research chemical, which exists in a legal gray zone rather than a clearly approved or clearly banned category; buyers should understand this before purchasing.

How does AOD-9604 pricing compare to other research peptides?

AOD-9604 sits in the middle of the research-peptide price range, generally $60-$200+ per vial, similar to many other unapproved peptides sold through the same channels. The more meaningful comparison isn't peptide-to-peptide price, it's AOD-9604's unconvincing obesity trial results versus approved drugs with actual placebo-beating Phase 3 data ^[1][7][8].

Should I buy AOD-9604 from the cheapest source I can find?

No. Given that the compound's own trial data didn't clearly beat placebo for fat loss ^[7][8], the money-smart move is either skipping it for an approved alternative or, if you proceed anyway, choosing a provider-reviewed source with documented sourcing over the cheapest anonymous listing, since sourcing risk is the one variable you can actually control.

Sources

1. FDA, Drugs@FDA approved drug products database: AOD-9604 has no FDA-approved listing, unlike approved obesity pharmacotherapies that cleared Phase 3 trials
2. 21 CFR 216.23, the 503A Bulks List: AOD-9604 is not on the FDA's 503A bulk drug substances list governing pharmacy compounding
3. 21 CFR 216.24, the 503B Bulks List: AOD-9604 is not on the FDA's 503B bulk drug substances list for outsourcing facilities
4. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: Explains the nomination and review process substances undergo before being added to compounding bulks lists
5. FDA, Bulk Drug Substances Nominated for Use in Compounding (current list): Lists substances under active nomination review for compounding use, the status category distinct from approval
6. 21 U.S.C. 353a, pharmacy compounding: Governs conditions under which pharmacy compounding is exempt from full new-drug requirements
7. PubMed PMID 15134286, Current Opinion in Investigational Drugs, 2004: Describes AOD-9604 as an hGH fragment engineered around the lipolytic fat-metabolizing region
8. PubMed PMID 16625817, Current Opinion in Investigational Drugs, 2006: Reviews obesity drugs in clinical development including AOD-9604 among candidates that did not reach approval
9. PubMed PMID 24124033, Drug Testing and Analysis, 2013: Found AOD-9604 does not influence the WADA hGH isoform immunoassay
10. PubMed PMID 24906629, Journal of Pharmaceutical and Biomedical Analysis, 2014: Covers analytical approaches for detecting emerging therapeutics and non-approved drugs including peptides in doping controls
11. PubMed PMID 25382550, Expert Review of Proteomics, 2014: Reviews detection strategies for peptidic drugs, candidates, and analogs in sports doping
12. PubMed PMID 26578461, Journal of Separation Science, 2016: Describes a direct urine injection LC/ion mobility mass spectrometry method for screening peptides under 2 kDa
13. PubMed PMID 41490200, JAAOS Global Research & Reviews, 2026: Reviews therapeutic peptides in orthopaedics including applications and challenges, a context distinct from fat-loss trials
14. PubMed PMID 41966639, Sports Medicine, 2026: Covers safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance
15. PubMed PMID 14685303, Methods and Findings in Experimental and Clinical Pharmacology, 2003: Tracked AOD-9604 among compounds in active clinical development during 2003
16. PubMed PMID 14571286, Methods and Findings in Experimental and Clinical Pharmacology, 2003: Second 2003 gateways entry tracking AOD-9604 in clinical development
17. PubMed PMID 15834452, Methods and Findings in Experimental and Clinical Pharmacology, 2005: 2005 gateways entry showing AOD-9604 still tracked in clinical development pipelines